title: Idelalisib--a PI3Kδ inhibitor for B-cell cancers.
authors.affiliation: From the Department of Molecular Biology and Biochemistry and Institute for Immunology, University of California, Irvine (D.A.F.); and Weill Cornell Medical College, New York (L.C.C.).
authors.forename: David A
authors.initials: DA
authors.lastname: Fruman
authors.forename: Lewis C
authors.initials: LC
authors.lastname: Cantley
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011687:Purines / Q000627:therapeutic use*; D052999:Quinazolinones / Q000627:therapeutic use*; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011687:Purines; D052999:Quinazolinones; D000069283:Rituximab; C552946:idelalisib